Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 6 de 6
1.
Eur J Case Rep Intern Med ; 11(6): 004390, 2024.
Article En | MEDLINE | ID: mdl-38846656

Late onset combined immunodeficiency (LOCID) is a rare variant of common variable immunodeficiency (CVID), typically affecting adult patients who present with opportunistic infections (OI) and/or low CD4+ T lymphocytes. Diagnostic delay is common due to the rareness of this entity, increasing morbidity and mortality. We report on a 66-year-old male who developed a severe gastrointestinal cytomegalovirus (CMV) infection, refractory to antiviral treatment and anti-cytomegalovirus specific human immunoglobulin administration, with a fatal outcome due to an undiagnosed LOCID. LEARNING POINTS: Infections in patients with primary immunodeficiencies (PIDs) could be more severe and life-threatening than in immunocompetent hosts.PIDs are not exclusive to paediatric patients; diagnostic delay is common, and they should also be suspected in adulthood.Diagnostic delay in PID patients is associated with more morbidity and mortality.

2.
Transpl Infect Dis ; 26(1): e14208, 2024 Feb.
Article En | MEDLINE | ID: mdl-38071458

BACKGROUND: Kidney transplantation is associated with a high risk of infectious complications due to immunosuppressive therapy. Although infections may be transmitted from donor to transplant recipient through contaminated preservation solution (PS), the clinical impact of this is not well-understood. METHODS: We retrospectively evaluated PS contamination rates in a series of 339 patients who underwent cadaveric renal transplant at our centre. All patients with a positive culture received targeted preemptive therapy (PET). RESULTS: Of the 339 PS samples, 136 (40.1%) were positive for a microorganism, mainly coagulase-negative staphylococci (CoNS; n = 89;60.5%), gram-negative bacilli (n = 31;21.1%), non-CoNS gram-positive cocci (n = 18;12.2%), and Candida spp (n = 2;1.4%). Of the 136 positive cases, 42 (30.9%) received PET (12.4% of the cohort). No cases of urinary tract infection, surgical site infection, or graft loss were observed. Overall, our findings indicate that PS contamination, mainly by saprophytic skin flora (CoNS) is common. Only 8% of patients required antibiotic or antifungal therapy. CONCLUSION: The infection transmission rate from donors to recipients was negligible (0%), perhaps due to the early initiation of a targeted PET after isolation of a recognized pathogen. More data from large, prospective studies are needed to confirm these findings.


Kidney Transplantation , Humans , Kidney Transplantation/adverse effects , Retrospective Studies , Candida , Gram-Negative Bacteria , Staphylococcus
3.
J Infect Dis ; 224(6): 1024-1028, 2021 09 17.
Article En | MEDLINE | ID: mdl-33475730

Two transplant recipients (1 kidney and 1 hematopoietic stem cell) received maribavir (MBV) after cytomegalovirus (CMV) infection clinically resistant to standard therapy. Both patients achieved CMV DNA clearance within 30 and 18 days; however, the UL97 C480F variant emerged, causing recurrent CMV infection after a cumulative 2 months of MBV and 15 or 4 weeks of ganciclovir treatment, respectively. C480F was not detected under ganciclovir before MBV treatment. Recombinant phenotyping showed that C480F conferred the highest level of MBV resistance and ganciclovir cross-resistance, with impaired viral growth. Clinical follow-up and genotypic and phenotypic studies are essential for the assessment and optimization of patients with suspected MBV resistance.


Benzimidazoles/therapeutic use , Cytomegalovirus Infections/drug therapy , Cytomegalovirus/drug effects , Drug Resistance, Viral/genetics , Ganciclovir/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Kidney Transplantation/adverse effects , Ribonucleosides/therapeutic use , Transplant Recipients , Adult , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Benzimidazoles/pharmacology , Cytomegalovirus/genetics , Drug Resistance, Viral/drug effects , Female , Ganciclovir/pharmacology , Hematopoietic Stem Cells , Humans , Mutation/drug effects , Organ Transplantation , Phosphotransferases (Alcohol Group Acceptor)/genetics , Phosphotransferases (Alcohol Group Acceptor)/therapeutic use , Ribonucleosides/pharmacology , Treatment Outcome
4.
Clin Neurophysiol Pract ; 6: 164-167, 2021.
Article En | MEDLINE | ID: mdl-35112035

INTRODUCTION: Although pentavalent antimonials are no longer considered the first-line therapy for visceral leishmaniasis in the developed world, they are still used in certain geographical areas and in refractory cases. These drugs have a great number of adverse effects; however, neurological toxicity has been rarely reported. CASE REPORT: We present a 56-year-old woman who required long-term treatment with antimonial drugs due to refractory visceral leishmaniasis and presented clinically with tremor of extremities, myoclonus, gait disturbances and epileptic seizures. The EEG showed increased beta rhythms and generalized epileptogenic activity. She had a slow but favorable response after the withdrawal of antimonials and the initiation of anticonvulsant therapy. CONCLUSION: Severe but reversible neurological toxicity is a rare adverse effect of prolonged antimonial treatment. More EEG record data are needed to support the suspicion of a possible increase of beta rhythms in this situation.

5.
Rev. esp. cardiol. (Ed. impr.) ; 73: 0-0, 2020. ilus, tab
Article Es | IBECS | ID: ibc-187748

La irrupción de la pandemia por COVID-19 está suponiendo un verdadero reto social y sanitario. Su rápida expansión hace que sean muchos los pacientes afectos que desarrollan clínica asociada, incluyendo síntomas cardiológicos. Los pacientes con afectación cardiaca son un grupo especialmente vulnerable, por su mayor riesgo de contagio y gravedad de la enfermedad. La insuficiencia cardiaca, incluyendo al trasplante cardiaco y las asistencias ventriculares, supone un grupo relevante dentro de los pacientes cardiológicos. Por ello, la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología ha elaborado una serie de recomendaciones para el abordaje de estos pacientes, en los diferentes escenarios en los que se pueden encontrar: ambulatorio y hospitalizado, con y sin COVID-19


The outbreak of the COVID-19 pandemic is a real social and healthcare system challenge. Its rapid expansion implies that many affected patients develop associated symptoms, including cardiological symptoms. Patients with cardiological diseases are at increased risk of being infected and the severity of the disease. Heart failure, including heart transplantation and ventricular assist devices, is a relevant group within the cardiological patients. For this reason, the following text has been intended to give a series of recommendations for the management of these patients, in the different scenarios in which they can be found: outpatient and hospitalized, with and without COVID-19


Humans , Heart Failure/complications , Heart Transplantation , Coronavirus Infections , Severe acute respiratory syndrome-related coronavirus/pathogenicity , Coronavirus Infections/prevention & control , Risk Adjustment , Vulnerable Populations/classification , Algorithms , Telemonitoring
6.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 30(supl.2): 10-18, Mar. 2012. tab
Article En | IBECS | ID: ibc-105871

La infección sigue siendo una complicación significativa tras el trasplante de órgano sólido (TOS). La incidencia de los diferentes patógenos varía ampliamente dependiendo de la presencia de factores específicos y, de acuerdo con esto, los pacientes pueden clasificarse en diferentes categorías de riesgo que precisarán estrategias profilácticas específicas para cada categoría. Deben tenerse en cuenta tanto los microorganismos de origen endógeno (colonización previa o infección latente) como los de nueva adquisición (infección primaria a partir del donante o del entorno). Las infecciones bacterianas predominan en los pacientes con estancias hospitalarias complejas o alteraciones anatómicas. Las infecciones virales, causadas tanto por virus oportunistas (citomegalovirus, virus de Epstein-Barr, virus BK, etc.) como por virus comunes (influenza, virus respiratorios, virus de la varicela zoster, etc.) son esenciales y pueden contribuir al rechazo crónico del trasplante. Las infecciones fúngicas no son habituales hoy en día, pero provocan una alta mortalidad y precisan profilaxis en un subgrupo de pacientes. Las infecciones parasitarias son una clara amenaza, principalmente en pacientes trasplantados que viajen a zonas endémicas. Los médicos que tratan a los receptores de TOS deben ser conscientes de estos factores de riesgo, que incluyen las características específicas del receptor, tipo de trasplante, microorganismo y planes de inmunosupresión (AU)


Infection remains a significant complication after solid organ transplantation (SOT). The incidence of various pathogens varies widely depending on the presence of specific factors, according to which patients can be classified into different risk categories that may merit tailored prophylaxis strategies. Both the endogenous origin of microorganisms (previous colonization or latent infection) and new acquisition (primary infection from donor or environment) should be considered. Bacterial infections predominate in patients with complex hospital stays or anatomical alterations. Viral infections, caused both by opportunistic (CMV, EBV, BKV, etc.) and common viruses (influenza, respiratory virus, VVZ, etc.), are of great importance, and may contribute to chronic rejection. Fungal infections are uncommon nowadays, but cause high mortality and deserve prophylaxis for a subset of patients. Parasitic infections are a clear threat, mainly in transplanted patients or those travelling to endemic areas. Physicians attending SOT recipients should be aware of these risk factors, which include specific host characteristics, type of transplantation, microorganism and immunosuppressive policy (AU)


Humans , Organ Transplantation/adverse effects , Antibiotic Prophylaxis , Infections/epidemiology , Risk Factors , Infection Control/methods
...